Quince Therapeutics, Inc. QNCX
31.00
1.00
3.33%
as of 25 Sep
- Market cap
- $30.5M
- P/E
- 0.0×
Follow QNCX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
14.52 | 2.92 | 0.53 | 1.12 |
+8 more quarters Free account |
Net Debt/EBITDA |
1.45 | 1.24 | (0.03) | 0.64 | |
Debt/Assets |
0.00% | 0.00% | 19.63% | 15.94% | |
Debt/Equity |
0.00 | 0.00 | (0.51) | 16.54 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.25 | (0.21) | 0.27 | 0.74 | |
Capex/Depreciation |
0.00 | 0.00 | 0.03 | 0.37 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.73 | 0.62 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(3.08) | (16.73) | (41.86) | (37.07) | |
Cash per Share |
18.91 | 39.83 | 70.87 | 97.44 | |
Shareholders Equity per Share |
(5.76) | 34.37 | (142.57) | 3.93 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(5.76) | 34.37 | (142.57) | 3.93 | |
Free Cash Flow |
(18.89) | (7.63) | (10.48) | (10.00) | |
Working Capital |
114.91 | 16.81 | (20.33) | 3.16 | |
Capital Expenditures |
— | — | 0.00 | (0.07) | |
Net Current Asset Value |
(35.91) | 14.63 | (106.34) | (79.64) | |
| Other line items | |||||
Quick Ratio |
13.64 | 2.07 | 0.41 | 1.01 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.08) | (16.73) | (41.84) | (36.80) | |
Capex per Share |
0.00 | 0.00 | (0.02) | (0.27) | |
Average Payables |
3.20 | 4.20 | 2.56 | 2.51 | |
Average Assets |
120.60 | 66.86 | 104.00 | 118.21 | |
Average Common Equity |
(11.79) | 17.13 | (2.78) | 23.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates